The company says “certain issues” prevented the FDA from evaluating the NDA within the six-month window allotted for Priority Review and hence ALO will resubmit the NDA later.
Oh puh-lease... What is this, silly season for biotech PR? Between INGN, BioVaxID, and this...
Market Data 
Markets 
AI
